The National Health Service (NHS) Cord Blood Bank in the United Kingdom has adopted Cells4Life Gold service method of cord blood volume reduction using Thermogenesis AXP System.
The NHS manages six umbilical cord blood facilities and a cord blood storage bank in the UK.
The upgrade by the NHS from the Sepax system to the more advanced Thermogenesis AXP system will ensure a number of benefits for the country’s cord blood bank. In comparison to the Sepax System, cord blood units processed using AXP are richer in Mononuclear Cells (MNCs) than units conventionally processed having similar Total Nucleated Cell Counts (TNC Counts). Stem cell recovery of units is greater than 97%, which is higher than Sepax and any other cord blood processing systems.
Cord Blood is the blood that remains in the placenta and umbilical cord after the baby is born. It is rich in stem cells which can help to cure and treat many life threatening diseases. The stem cells found in cord blood restore the function of the patient’s immune system and blood producing systems. It is an alternative to using bone marrow with the advantage of being immediately available if required for treatment.
The United Kingdom Department of Health in collaboration with NHSBT has established new targets for both cell collection activity and cell counts processed from cord blood, and are providing expanded funding to support cord blood collection programs over the next three years. These new targets mean that collection could potentially double in the UK.
Thermogenesis (NASDAQ: KOOL) is a developer of separation, preservation and storage technologies for human blood and tissue.